论文部分内容阅读
目的探讨分析瑞格列奈联合地特胰岛素注射液治疗2型糖尿病的临床疗效。方法 380例2型糖尿病患者,随机分为观察组和治疗组,各190例。观察组患者仅服用瑞格列奈进行治疗,治疗组患者服用瑞格列奈与皮下注射地特胰岛素联合治疗。根据指标变化调整服药剂量,观察治疗12周后两组患者的空腹血糖(FPG)水平、糖化血红蛋白(Hb A1c)水平和餐后2 h血糖(2 h PBG)水平;结果治疗前后,患者的FPG、2 h PBG和Hb A1c变化显著,差异有统计学意义(P<0.05);观察组治疗有效率为80.53%,实验组为94.21%,差异有统计学意义(P<0.05);结论瑞格列奈与地特胰岛素联用药治疗2型糖尿病的疗法,临床疗效较优,可显著降低患者低血糖发生率,且患者的依从性好,可作为临床主要疗法进行推广。
Objective To investigate the clinical efficacy of repaglinide combined with insulin injection in the treatment of type 2 diabetes mellitus. Methods 380 patients with type 2 diabetes were randomly divided into observation group and treatment group, each of 190 cases. Patients in the observation group were treated with repaglinide only, and patients in the treatment group were treated with repaglinide in combination with repaglinide. The dose of FPG was adjusted according to the change of indexes. The levels of fasting blood glucose (FPG), Hb A1c and 2 h postprandial blood glucose (2 h PBG) were observed after 12 weeks of treatment. Results Before and after treatment, FPG , 2 h PBG and Hb A1c changes significantly, the difference was statistically significant (P <0.05); observation group, the effective rate was 80.53%, 94.21% in the experimental group, the difference was statistically significant (P <0.05) The combination therapy of Leneed and insulin detemir is effective in treating type 2 diabetes mellitus, which can significantly reduce the incidence of hypoglycemia in patients with good compliance and can be used as the main clinical therapy.